A B S T R A C T
Background: Dietary restriction and phosphate binders are the main interventions used to manage hyperphosphatemia in people on hemodialysis, but have limited efficacy. Modifying conventional dialysis regimens to enhance phosphate clearance as an alternative approach remains relatively unstudied. Methods: This was a 10-week, 2-arm, randomized crossover study. Participants were prevalent dialysis patients (n ¼ 32) with consecutive serum phosphate levels >1.6 mmol/L and on stable doses of a phosphate binder. Following a 2-week run-in period, participants were randomized to initiate dialysis using two high flux dialyzers in parallel (blood flow !350 mL/min, dialysate flow 800 mL/min) or standard dialysis using one high flux dialyzer (blood flow !350 mL/min, dialysate flow of 800 mL/min). Each regimen was 3 weeks in duration. After a 2-week washout period, participants received the alternate regimen. The primary outcome was the mean difference in phosphate clearance by dialyzer strategy. Secondary outcomes were phosphate removal and pre-dialysis serum phosphate. Results: Phosphate clearance for the double dialyzer strategy did not differ significantly from the single dialyzer strategy [mean difference 7.5 mL/min (95% confidence interval, 95% CI, À6.1, 21.0), P ¼ 0.28]. There was no difference in total phosphate removal and pre-dialysis phosphate between the double and single dialyzer strategies [total phosphate removal mean difference À0.2 mmol (95% CI À4.1, 3.7), P ¼ 0.93; pre-dialysis mean difference 0.01 mmol/L (95% CI À0.18, 0.21), P ¼ 0.88]. There was no difference in the proportion of participants who experienced at least one episode of intradialytic hypotension (32 versus 47%, P ¼ 0.13). A limitation of the study was frequent protocol deviations in the dialysis prescription. Conclusions: In this study, the use of two dialyzers in parallel did not increase phosphate clearance, phosphate removal or pre-dialysis serum phosphorus when compared with a standard dialysis treatment strategy. Future studies should continue to evaluate novel methods of phosphate removal using conventional hemodialysis.
Keywords: clinical trial, dialysis, dialysis adequacy, ESRD, phosphatemia

I N T R O D U C T I O N
Elevated serum phosphate is central to the hormonal dysregulation that underlies disordered bone and mineral metabolism in chronic kidney disease (CKD). Numerous observational studies have reported the independent association between derangements in mineral metabolism (hyperphosphatemia, hyperparathyroidism, elevated fibroblast growth factor and deficient calcitriol) and increased morbidity and mortality in people with advanced CKD [1] [2] [3] [4] . Although it is unknown whether better control of hyperphosphatemia would improve clinical outcomes, interventions to normalize serum phosphorus have been a significant focus of nephrology practice and are recommended by current clinical practice guidelines [5] .
Along with dietary phosphate restriction, calcium-based phosphate binders have traditionally been the cornerstone of treatment for hyperphosphatemia. However accelerated cardiovascular disease in advanced CKD [6] [7] [8] , and observational data suggest that higher doses of calcium-based phosphate binders may contribute to vascular calcification [9] . Therefore, there has been considerable interest in controlling serum phosphate while minimizing oral calcium load. While most attention has focused on the use of non-calcium containing phosphate binders such as sevelamer [10] and lanthanum [11] , modifying conventional dialysis regimens to improve phosphate clearance is an alternative approach that remains relatively unstudied.
A secondary analysis from a previously conducted randomized trial suggested that the use of two dialyzers in parallel might reduce serum phosphate levels in large patients (>80 kg) whose dialysis adequacy (assessed by Kt/V) was low at baseline [12] . However, the study was small and the results require confirmation. We designed the current study to examine whether the use of two dialyzers in parallel would result in increased phosphate clearance among hemodialysis patients with hyperphosphatemia, when compared with a standard single dialyzer. Secondary objectives were to determine whether the double dialyzer strategy results in lower pre-dialysis serum phosphate levels or increased phosphate removal in dialysate among hemodialysis patients with hyperphosphatemia.
M A T E R I A L S A N D M E T H O D S
Participants
This crossover trial was performed at two university-based outpatient dialysis units in the province of Alberta, Canada. The dialysis units are located in Edmonton and Calgary. Participants from both sites were screened for eligibility from January 2013 to August 2014. The health research ethics boards at the universities of Calgary and Alberta approved this study.
Inclusion criteria were: !18 years of age, stable on hemodialysis for at least 3 months, receiving three dialysis treatments per week, blood flow rate !350 mL/min through a well-functioning access, serum phosphate levels >1.6 mmol/L on two consecutive lab tests at least 4 weeks apart and no changes in phosphate binder dose in the 4 week period prior to enrolment. Exclusion criteria were: scheduled kidney transplant or surgery or hospitalization, planned switch in dialysis modality or move from the study site, predicted life expectancy shorter than 3 months, contraindication to intradialytic anticoagulation, missing more than eight dialysis treatments in the past 3 months, or nonadherence to other aspects of the dialysis treatment, enrolled in another clinical trial or inability to provide informed consent.
Intervention
This was a 10-week, 2-arm, randomized, crossover trial (registration number NCT01539252) comparing the effects of one versus two dialyzers in parallel. Participants were randomly assigned in a 1:1 ratio to receive for a 3-week period either (i) standard dialysis using one high flux dialyzer, blood flow of !350 mL/min and dialysate flow of 800 mL/min or (ii) dialysis using two high flux dialyzers in parallel, blood flow of !350 mL/min and dialysate flow of 800 mL/min (where blood and dialysate flow was split equally between the two dialyzers using a Y-connector). After a 2-week washout period, participants received the alternate regimen. During the washout period, all participants were dialyzed with a single dialyzer. All study participants were dialyzed with Xenium 190 dialyzers (Baxter Canada). Participants underwent a 2-week run-in period (six treatments) with the new, single dialyzer at a dialysate flow of 800 mL/min to ensure tolerability. The duration of the dialysis session remained unchanged from the participants' baseline, typically 3.5-4.5 h. All patients were asked to maintain a similar dietary (and by extension phosphate) intake during the study. No changes in oral phosphate binders, vitamin D analogs or calcimimetics were permitted during the study.
Randomization, allocation concealment and blinding
All participants were randomly assigned to the intervention order using a permuted block design. Randomization occurred during the last mid-week session of the run-in period. The randomization list was generated by the statistician and kept in a locked cabinet. Treatment allocation was concealed using sequentially numbered, opaque and sealed envelopes. To reduce the likelihood of deliberate dietary changes, patients were blinded to study hypothesis. For safety and for logistical reasons, dialysis staff must be able to clearly see and access the dialyzers at all times; therefore, patients, study staff and investigators were unblinded to treatment allocation. Lab personnel who were involved in outcome ascertainment (serum specimen assays) were unaware of the therapy that participants had received.
Data collection
Data were collected via participant interviews and through chart and clinical database review at baseline (i.e. the mid-week dialysis session in the week prior to the first study treatment), Week 3 (i.e. the mid-week dialysis session during the last week of the first treatment received), Week 5 (i.e. the mid-week dialysis session during the last week of the washout period between treatments) and Week 8 (i.e. the mid-week dialysis session during the last week of the second treatment received). Medical history, medication use, cause of renal failure, length of time on dialysis, type of vascular access and demographics were ascertained at baseline. Adverse event reviews were completed at each study visit and 30 days following the discontinuation of the trial intervention.
Blood and dialysate sampling
During the designated treatments (baseline, Weeks 3, 5 and 8), qualified dialysis unit personnel drew pre-and post-dialysis blood samples from the arterial port. The post-dialysis blood samples were drawn after decreasing the pump speed to 50 mL/ min [13] . Blood samples were analyzed for serum phosphate, creatinine calcium, total protein, albumin, potassium, urea, platelet count, beta-2-microglobulin and cystatin C. Dialysate was collected using a fractional collection method [14] . Dialysate samples were analyzed for urea and creatinine at local laboratories at each site (Alberta Health Services Laboratory Services for Edmonton; Calgary Laboratory Services for Calgary). Given the very low phosphate concentrations in dialysate, frozen dialysate samples were sent to a reference laboratory for phosphate analysis (Nephrology Research Lab, University of Louisville, KY, USA).
The primary (phosphate clearance) and secondary (pre-dialysis serum phosphate and phosphate removal) outcomes were measured at baseline, and Weeks 3, 5 and 8. Phosphate clearance and removal were determined by the direct dialysate quantification method, using the formulas found in Katopodis et al. [15] . Serious adverse events (hospitalizations related to dialysis) and intradialytic hypotensive events (defined a priori as a symptomatic decrease in systolic blood pressure by !20 mmHg that required an intervention) were collected by patient report and review of the medical record during the study visits.
Sample size
The secondary outcome of phosphate removal required a larger sample size than the primary outcome of phosphate clearance, and thus was selected for choosing the final sample size. A sample size of 33 was used to provide 80% power (with a 5% Type 1 error rate and 10% drop-out) to detect a difference in phosphate removal of 11 mmol between the double dialyzer and single dialyzer strategies. A standard deviation of 21 mmol for the difference in phosphate removal between strategies was assumed. No interim analyses were planned or performed due to the short duration of the trial.
Statistical analyses
All analyses were completed in Stata/MP 13.0 (www.stata. com) and followed an intention-to-treat approach. Baseline descriptive statistics were reported as counts and percentages, medians and interquartile ranges (IQRs) or means with standard deviation.
We used a linear mixed effects regression model to account for the non-independence of repeated outcome measures. This analysis was used to determine the efficacy of the dialyzer strategies (within participant treatment effect), as well as period effect (between participant treatment effect), and the carry-over effect (participant by sequence effect). The normality assumption for outcomes variables was evaluated and met. Participants were modeled as random effects and initially, treatment, period, sequence and site were modeled as fixed effects. There was no evidence of period or carry-over effects; therefore, these terms were excluded from the final model. The final models were adjusted for pre-dialysis serum phosphate at baseline and during the washout (i.e. 'rolling baseline' serum phosphate) as a fixed effect. Mean differences are reported along with 95% confidence intervals (95% CI). P < 0.05 was considered statistically significant.
The following sensitivity analyses were planned a priori: imputing missing outcome data using a last-value carried forward approach and a per-protocol analysis including only the participants that completed at least three treatments for at least one treatment strategy.
R E S U L T S
This trial is reported according to the CONSORT guidelines. The dataset was locked on 8 May 2015.
Participant flow
Trial flow is presented in Figure 1 . A total of 142 hemodialysis patients met the eligibility criterion of serum phosphate levels >1.6 mmol/L on two consecutive lab tests at least 4 weeks apart. Of those 142 participants who met the laboratory criterion for hyperphosphatemia, 72 were subsequently found to be ineligible, 16 declined participation and 21 of the initial 142 screened were not approached. The main reason for ineligibility was an improvement in serum phosphorus (<1.6 mmol/L) (n ¼ 16) and other reasons (n ¼ 24) (mainly due to dialysis treatment time <3.5 h and isolation precautions). Thirty-three patients were randomized and 31 completed the study. Two participants experienced adverse events and withdrew from the study treatment. One of the withdrawals was due to a serious adverse event that occurred before the intervention was initiated, 1 day after baseline information was collected; therefore, analyses and information are presented for the remaining 32 individuals.
Baseline data
Study participants were predominantly male (72%), white (72%), with a median age of 64 years (IQR 54, 76) ( Table 1) . Most participants were dialyzing through a fistula (84%). The primary cause of end-stage renal disease (ESRD) was diabetes (50%), followed by glomerulonephritis (19%) and hypertension (19%). Hypertension was present among 94% of participants, 63% were diabetic, 31% had a history of congestive heart failure and 28% had coronary artery disease. Most participants were taking a phosphate binder (94%) and 44% were taking calcitriol. At baseline, mean phosphate clearance, phosphate removal and pre-dialysis serum phosphate were 120 mL/min [standard deviation (SD) 33], 37 mmol (SD 14) and 2.0 mmol/L (SD 0.6), respectively.
Outcomes
As expected, mean phosphate clearance, phosphate removal and pre-dialysis serum phosphate were similar during the washout period (data not shown). In the final model, adjusting for 'rolling' serum phosphate and site, the phosphate clearance for the double dialyzer strategy was 7.5 mL/min higher than the single dialyzer strategy, but was not significant [mean difference 7.5 mL/min (95% CI À6.1, 21.0), P ¼ 0.28]. In our main analysis, there was no difference in total phosphate removal or predialysis phosphate between the double and single dialyzer strategies [mean difference in total phosphate removal, À0.2 mmol (95% CI À4.1, 3.7), P ¼ 0.93; mean difference in pre-dialysis serum phosphate, 0.01 mmol/L (95% CI À0.18, 0.21), P ¼ 0.88] ( Table 2) . Results were similar when missing values were imputed (results not shown). Per-protocol analyses were not performed as no individuals were excluded for not completing at least three sessions for either treatment strategy.
Adverse events
Serious adverse events were reported for 1 (3%) and 3 (9%) of the 31 and 32 participants receiving the single and double dialyzer strategies, respectively (Table 3 ). There was no difference in the proportion of participants who experienced at least D o u b l e d i a l y z e r f o r e n h a n c e d p h o s p h a t e c l e a r a n c e The withdrawal due to a serious adverse event during the study period was a pleural effusion with presentation to the emergency department. This episode was determined to be unrelated to the study treatment.
Protocol deviations
Protocol deviations were frequent overall: 28 of the 31 (90%) participants in the single dialyzer treatment arm and 26 of the 32 (81%) participants in the double dialyzer treatment arm had at least one protocol deviation. The most common protocol deviation was blood flow <350 mL/min (68 versus 69% with at least one deviation) and treatment time <3.5 h (35 versus 31% with at least one deviation) for the single versus the double dialyzer strategies, respectively.
The mean blood flow and the treatment time delivered in the single dialyzer arm and the double dialyzer arm were similar: 367 mL/min (SD 40) and 365 mL/min (SD 46), respectively. Median treatment time between the two groups was also similar: 4.0 h (IQR 3.6, 4.0) in the single dialyzer arm and 4.0 h (IQR 3.5, 4.0) in the double dialyzer arm. Although phosphate and urea follow different kinetics [16] , to confirm the integrity of the double dialyzer intervention we estimated differences in mean Kt/V between the study arms: 1.44 (SD 0.26) in the single dialyzer arm versus 1.63 (SD 0.32) in the double dialyzer arm.
D I S C U S S I O N
Few studies have evaluated how to modify conventional dialysis treatment to improve phosphate removal. Two small studies have shown that increasing membrane surface area can increase phosphate clearance [17, 18] and in our previous study of large (>80 kg) hyperphosphatemic hemodialysis patients, we found that two dialyzers in parallel decreased pre-dialysis serum phosphate by 0.43 mmol/L compared with a single dialyzer [12] . However, in the current randomized crossover trial among patients with hyperphosphatemia, we found no difference in phosphate clearance, total phosphate removal or pre-dialysis phosphate with a double dialyzer versus a single dialyzer strategy.
Although there are no placebo-controlled trials showing that lowering serum phosphate to a specific target leads to improvements in clinically important outcomes, based on results from observational studies, nephrology clinical practice guidelines continue to endorse the normalization of serum phosphorus [5] . Common approaches to phosphate management in ESRD include dietary restriction, phosphate binders and increasing the frequency or duration of dialysis. However, the limitations of these interventions are made evident by the high proportion of patients with serum phosphate above the recommended guideline. Based on data from The International Dialysis Outcomes and Practice Patterns Study, 47% of patients had a serum phosphate above the target level [19] . Dietary restriction of phosphate is the cornerstone of therapy; however, given the high phosphate content of the typical Western diet [20] , these restrictions are notoriously difficult to follow and may negatively affect patients' nutritional status by limiting the intake of readily available sources of protein [21] . Consequently, oral phosphate binders are frequently prescribed to correct hyperphosphatemia. In addition to their well-recognized side effects [22] , for people on dialysis, phosphate binders account for approximately one-half of the daily pill burden and higher pill burden has been associated with lower health-related quality of life [23] . For the treatment of persistent hyperphosphatemia, KDIGO guidelines recommend increasing dialytic phosphate removal [5] . One recent study demonstrated that dialysis treatment time was more influential than frequency in lowering predialysis phosphate [24] . This finding is consistent with the conventional wisdom that the rate of transfer between the intra and extracellular compartments is the key determinant of phosphate removal [16] . However, this option is not feasible for all hemodialysis centers and may not be acceptable to many patients.
One potential explanation for the limited number of studies evaluating phosphate removal during conventional hemodialysis is that the underlying physiology is not completely understood. In the first 1-2 h of the dialysis treatment, serum phosphate rapidly decreases. After this initial decline, the serum concentration of phosphate remains at a constant concentration then rebounds in the post-dialysis period [25] [26] [27] . Studies have also shown a rebound in serum phosphate concentration prior to the end of dialysis [27, 28] . Several kinetic models have been proposed to explain these observations. The three compartment model is similar to the two-compartment model for describing urea kinetics with the addition of an unidentified third compartment that releases phosphate into the extracellular space once the intracellular phosphate concentration drops below an intrinsic intracellular target [29] . To explain the intradialytic increase in serum phosphate, Spalding et al. [29] proposed an additional fourth pool, located in the intracellular space, that controls phosphate release in response to critically low intracellular phosphate concentrations. More recently, a simplified pseudo-one compartment model of phosphate kinetics has been proposed [30] . In this model, phosphate is removed from a central compartment, accessible to the dialyzer. Phosphate is continuously mobilized to this central pool from a larger, undefined volume of phosphate (representing a combination of all inaccessible phosphate pools) and in proportion to the phosphate mobilization clearance (a measurement of the rate of . In an analysis of data from the HEMO study, Leypoldt et al. [31] evaluated the factors determining phosphorus mobilization in 774 patients. Those with larger phosphate mobilization clearances were able to maintain higher intradialytic serum phosphorus concentrations and consequently, higher total amounts of phosphorus removal. The factors associated with a higher clearance were male gender, a higher post-dialysis body weight and, consistent with previous models [29] , a lower predialysis serum phosphate concentration. Based on this theoretical understanding of phosphate kinetics, there are several potential reasons why increasing dialyzer surface area did not significantly improve outcomes in this study. First, according to two-compartment kinetic models, intercompartmental clearance is proportional to body weight [32] ; therefore, larger patients would mobilize phosphorus into the extracellular fluid for removal more rapidly. Consistent with this concept, our previous study in larger hemodialysis patients showed that use of two dialyzers led to a significant reduction in pre-dialysis phosphate levels and improved phosphate clearance. Although the experimental treatment did not enhance phosphate removal, this finding could have been due to a relatively insensitive laboratory assay for dialysate phosphate or because of low statistical power. Second, although the rate of phosphorus mobilization has been shown to vary among patients, similar values have been reported for within-patient observations during both short (2 h) and conventional (4 h) dialysis treatments. This finding suggests that additional unidentified individual factors may influence phosphate removal, independent of the dialysis treatment [30] . Third, in the current study, we did not quantify adherence to phosphate binders during the study period or estimate changes in dietary phosphate intake and it is possible that this confounded our results. In addition, although the median duration of hemodialysis was over 3 years, information on residual renal function was not available. Fourth, the duration of the intervention was relatively short (3 weeks) and there was a relatively high number of protocol deviations in this study, which could have biased results to the null. Finally, it is also possible that increasing dialyzer surface area does not actually increase dialytic removal of phosphorus, and that the results of our prior study were due to bias or chance.
In conclusion, we found that increasing dialyzer surface area by using two dialyzers in parallel did not increase phosphate clearance, removal or pre-dialysis serum phosphate. In order to increase phosphate removal with conventional hemodialysis, future studies should continue to evaluate phosphate physiology in the intradialytic period. Second, future trials evaluating the effect of modifying the dialysis treatment to improve phosphate removal should consider focusing on patients with larger total body water, and should include clinically meaningful outcomes, such as quality of life, hospitalization and survival.
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